IP Library Granted Patent US 7,465,572
Granted Patent B2
US 7,465,572 · App. 11/516,295 · Granted Dec 16, 2008

De-immunized streptokinase

Assignee: Merck Patent GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,465,572
App. No.
11/516,295
Granted
Dec 16, 2008
Kind
B2
Abstract

A target protein is rendered less immunogenic to a given species by (a) determining at least part of the amino acid sequence of the target protein; (b) identifying in the amino acid sequence one or more potential epitopes for T-cells (“T-cell epitopes”) of the given species; and (c) modifying the amino acid sequence to eliminate at least one of the T-cell epitopes identified in step (b) to reduce the immunogenicity of the protein when exposed to the immune system of the given species.

Claims (2)

1. An isolated protein comprising a modified streptokinase having the amino acid sequence set forth in SEQ ID NO: 253.

2. A pharmaceutical composition comprising an isolated protein of claim 1 in a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2007
From: BIOVATION LIMITED
To: MERCK PATENT GMBH
Reel/Frame 020259/0526 →
Priority Claims (4)
GB 9710480.6 · May 21, 1997 · national
GB 9716197.0 · Jul 31, 1997 · national
GB 9725270.4 · Nov 28, 1997 · national
GB 9807751.4 · Apr 14, 1998 · national
Continuity (5)
Division 1030021500 · Nov 20, 2002
Continuation 0943813600 · Nov 10, 1999
Continuation PCTGB980147300 · May 21, 1998
Provisional Application 6006723500 · Dec 2, 1997
Related Publication 20070014796A1 · Jan 18, 2007